Navigation Links
Transcatheter Technologies Successfully Performs in Vivo Implantation of the Trinity Transapical Aortic Valve System
Date:9/16/2010

Transcatheter Technologies Successfully Performs in Vivo Implantation of the Trinity Transapical Aortic... -- REGENSBURG, Germany, September 16, 2010 /PRNewswire/ --


Advanced Search Search

  
Close
  1. Send a release
  2. Member sign in
  3. Become a member
  4. For journalists
  5. Global sites
PR Newswire: news distribution, targeting and monitoring
  1. Products & Services
  2. Knowledge Center
  3. Browse News Releases
  4. Contact PR Newswire
Health Care & Hospitals, Medical Equipment, Medical Pharmaceuticals, Clinical Trials & Medical Discoveries Click to view news release full screen  

Transcatheter Technologies Successfully Performs in Vivo Implantation of the Trinity Transapical Aortic Valve System

 

REGENSBURG, Germany, September 16, 2010 /PRNewswire/ --

- Transapical Implantation of a Percutaneous Aortic Tissue Valve Validates Trinity's Technology

Transcatheter Technologies GmbH (TT), an innovative medical device company that is developing a second-generation transcatheter aortic valve prosthesis, announced today that its proprietary transapical aortic valve has been successfully implanted in the acute porcine model.

The acute in vivo study of the Trinity system has shown: 1) Accurate stepwise positioning of Trinity via an antegrade transapical approach. 2) Full expansion and anchoring of the Trinity valve prosthesis before the refolding of the stent. 3) Complete evaluation of the fully expanded prosthesis' function before refolding and repositioning or retrieval. 4) Detachment of the stent from the catheter without changing the geometry of the deployed valve prosthesis. 5) Outstanding anchoring and sealing due to the unique design of the stent. 6) Low transvalvular gradients.

TT's unique true repositioning system allows for complete expansion of the valved stent and full evaluation of prosthesis' function before repositioning, before retrieval, and before final release.

"Our aim is to remove the risks and anxiety associated with current transcatheter valve implantation procedures. Trinity's true repositioning technology allows the user to fully expand and anchor the valve, then evaluate hemodynamic valve function before separating from the catheter," said Hou-Sen Lim, CTO. "Our proprietary pre-mounted valve technology removes the need to mount the valve onto the catheter system in the operating room prior to the procedure, thereby reducing the cost and eliminating the risk associated with mounting the valve by an assistant at the implantation side."

"Trinity protects the fragile valve leaflets by Zero Pressure Crimping. This prevents crushing and damaging of the leaflets when the frame is folded. We expect that this will increase the lifespan of the valve prosthesis and thereby allowing for implantation in even younger patients," commented Wolfgang Goetz MD, PhD, CEO. "Our animal trials validate the feasibility of the technology in vivo. We are very proud to have achieved this significant milestone within a very short period of time."

Transcatheter Technologies successful closed the seed financing round in 2009 with High-Tech Gründerfonds and Seedfonds Bayern. The investment will be used for the development of a novel biological heart valve up to the proof of concept. "Transcatheter Technologies' valve design can solve major problems of common prosthesis. Thereby, valve implantations become an option for currently untreatable patients. We are convinced that the medicinal as well as technological expertise of the team provide an ideal base for a successful corporate development", adds Dr. Michael Nettersheim from High-Tech Gründerfonds.

About Transcatheter Technologies GmbH

Transcatheter Technologies GmbH is a privately held medical device company, founded in January 2009, and headquartered in Regensburg, Germany. The Trinity transapical aortic valve system's valve prosthesis is premounted on the catheter. Trinity's unique features enable true repositioning and Zero Pressure Crimping, which improve valve durability and broaden the scope of application of transcatheter valve implantations across a larger patient population. Trinity valve prosthesis is comprised of a bovine pericardium valve that is mounted on a self-expanding nitinol frame. Its implantation is performed transapically on a beating heart without the need for open-heart surgery.

For more information, contact Wolfgang Goetz, MD, PhD, CEO (wolfgang.goetz@transcatheter-technologies.com) or Hou-Sen Lim, MEng, CTO, (hou-sen.lim@transcatheter-technologies.com), Transcatheter Technologies GmbH, BioPark Regensburg, Josef-Engert-Str. 11, 93053 Regensburg, Germany, +49-170-6309920/21.

About High-Tech Gründerfonds

High-Tech Gründerfonds invests risk capital in young, high-potential technology companies that convert promising research results in business success. The seed finance provided aims to enable start-ups to take their R&D project through to the creation of a prototype, a proof of concept or to market launch. Investors in this public/private partnership are the German Federal Ministry for Business and Technology, the KfW Banking Group as well as the six industrial groups of BASF, Deutsche Telekom, Siemens, Robert Bosch, Daimler and Carl Zeiss. High-Tech Gründerfonds has a fund volume of about 272 million euros.

For more information, contact Dr. Michael Nettersheim, Senior Investmentmanager, High-Tech Gründerfonds Management GmbH, Ludwig-Erhard-Allee 2, 53175 Bonn, Germany, Phone:+49-228-96568500,Fax: +49-228-96568550, http://www.high-tech-gruenderfonds.de.


'/>"/>
SOURCE Transcatheter Technologies GmbH
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. XTENT Announces Clinical Trial Data to be Presented at Annual Meeting of Transcatheter Cardiovascular Therapeutics Next Week
2. InfraReDx to Showcase the LipiScan(TM) Coronary Imaging System at the Cardiovascular Research Foundations (CRF) Annual Transcatheter Cardiovascular Therapeutics (TCT) Scientific Meeting
3. Emisphere Technologies, Inc. Announces 2007 Second Quarter Financial Results
4. King Pharmaceuticals and Palatin Technologies Delay Immediate Plans for Phase 3 Clinical Program With Bremelanotide for Erectile Dysfunction
5. Rockwell Medical Technologies, Inc. Begins Patient Enrollment for its SFP Dose-Ranging Study
6. Rockwell Medical Technologies, Inc. Begins Dosing Patients for SFP Phase IIb Clinical Study
7. New Clinical Studies Confirm Mauna Kea Technologies Cellvizio(R) GI in Range of Procedures
8. Palatin Technologies, Inc. Reports Initiation of Human Trials for the Treatment of Congestive Heart Failure
9. Emisphere Technologies, Inc. Announces 2007 Third Quarter Financial Results
10. Senesco Technologies Initiates Preclinical Studies for Cancer Target
11. ASEAN News: Epeius Biotechnologies Gains Commercial Approval for Rexin-G(R), a Tumor-Targeted Gene-Based Medicine for Metastatic Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... , June 24, 2016   Pulmatrix, Inc ... company developing innovative inhaled drugs, announced today that it ... Russell Investments reconstituted its comprehensive set of U.S. ... "This is an important milestone for Pulmatrix," said ... increase shareholder awareness of our progress in developing drugs ...
(Date:6/23/2016)... June 23, 2016  MedSource announced today that ... e-clinical software solution of choice.  This latest decision ... value to their clients by offering a state-of-the-art ... relationship establishes nowEDC as the EDC platform of ... full-service clients.  "nowEDC has long been a preferred ...
(Date:6/23/2016)... -- Research and Markets has announced the ... (Organic Chemical (Sugar, Petrochemical, Glycerin), Inorganic Chemical), Functionality (Filler, ... Global Forecast to 2021" report to their offering. ... pharmaceutical excipients market is projected to reach USD 8.1 ... the forecast period 2016 to 2021. ...
Breaking Medicine Technology:
(Date:6/27/2016)... ... June 27, 2016 , ... ... professionals, announced today its affiliation with Tennessee Counseling Association. This new ... network of the Tennessee Counseling Association, adding exclusive benefits and promotional offers. , ...
(Date:6/26/2016)... ... June 27, 2016 , ... Quality metrics are proliferating in ... ways they remain in the eye of the beholder, according to experts who offered ... The American Journal of Managed Care. For the full issue, click here . ...
(Date:6/26/2016)... ... June 26, 2016 , ... Brent Kasmer, a legally blind and certified personal trainer ... through a fitness app. The fitness app plans to fix the two major problems leading ... a one size fits all type program , They don’t eliminate all the ...
(Date:6/25/2016)... ... 25, 2016 , ... The temporary closing of Bruton Memorial Library on June 21 due to ... a new, often overlooked aspect of head lice: the parasite’s ability to live away from ... common occurrence, but a necessary one in the event that lice have simply gotten out ...
(Date:6/25/2016)... ... June 25, 2016 , ... ... recover from injury. Recently, he has implemented orthobiologic procedures as a method for ... is one of the first doctors to perform the treatment. Orthobiologics are substances ...
Breaking Medicine News(10 mins):